Vaccines Against SARS-CoV-2 in Psoriasis Patients on Immunosuppressive Therapy: Implications of Vaccination Nationwide Campaign on Clinical Practice in Italy.
COVID-19
Dermatology
Pandemic
Psoriasis
SARS-CoV-2
Vaccines
Journal
Dermatology and therapy
ISSN: 2193-8210
Titre abrégé: Dermatol Ther (Heidelb)
Pays: Switzerland
ID NLM: 101590450
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
02
08
2021
pubmed:
30
9
2021
medline:
30
9
2021
entrez:
29
9
2021
Statut:
ppublish
Résumé
More than 12 months have passed since the World Health Organization (WHO) declared Coronavirus Disease 19 (COVID-19), caused by the SARS-CoV2 virus, to be a pandemic on 11 March 2020. The entire world scientific community agrees that at this time vaccine is the most promising weapon to combat the infection and the severity of the disease. According to the document "Draft landscape of COVID-19 candidate vaccines" by WHO, 272 vaccines against SARS-CoV-2 virus are in development, although only four of these, produced by Pfizer-BioNTech (Pfizer, Inc. and BioNTech), Moderna, AstraZeneca, and Janssen companies, respectively, have been approved by European Medicines Agency and Italian Medicines Agency and subsequently distributed nationwide for use. These vaccines are the result of highly innovative procedures and are quite different from each other in terms of composition. Even clinicians in various medical fields may be unfamiliar with the effects of these vaccines. There is the strong emerging need for dermatologists to understand the crucial role of vaccines, with a focus on the need to vaccinate patients suffering from immune-mediated skin diseases, such as psoriasis, while taking the ongoing treatment into consideration regarding the timing of vaccination. Similarly, psoriasis patients aware of having an immune-mediated and inflammatory disease are increasingly asking the dermatologist information about the efficacy and safety of vaccines against SARS-CoV-2 virus. In this narrative review of the literature and critical analysis of the recommendations of the Italian Ministry of Health, we analyze the implications of the vaccination campaign on dermatological patients with psoriasis undergoing immunosuppressive treatment.
Identifiants
pubmed: 34586598
doi: 10.1007/s13555-021-00610-z
pii: 10.1007/s13555-021-00610-z
pmc: PMC8480269
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1889-1903Informations de copyright
© 2021. The Author(s).
Références
Diotallevi F, Radi G, Campanati A, et al. Time to restart: protocol of resumption of activities of a dermatological clinic of a level II hospital in the COVID-19 era. Int J Dermatol. 2020;59(11):1411–3.
doi: 10.1111/ijd.15187
pubmed: 32966610
World Health Organization. Draft landscape of COVID-19 candidate vaccines. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines . Accessed 14 Apr 2021.
Radi G, Simonetti O, Diotallevi F, et al. How can I take care of you? The dermatologist meets patients’ needs during the COVID-19 pandemic. Dermatol Ther. 2020;33(4):e13740.
doi: 10.1111/dth.13740
pubmed: 32478970
European Medicines Agency. COVID-19 vaccines. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines . Accessed 14 Apr 2021.
Agenzia Italiana del Farmaco (Italian Medicines Agency). Vaccini COVID-19. https://www.aifa.gov.it/vaccini-covid-19 . Accessed 14 Apr 2021.
Polack FP, Thomas SJ, Kitchin N, et al. C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–15.
doi: 10.1056/NEJMoa2034577
pubmed: 33301246
Baden LR, El Sahly HM, Essink B et al. COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2020;384(5):403–16.
doi: 10.1056/NEJMoa2035389
pubmed: 33378609
Agenzia Italiana del Farmaco (Italian Medicines Agency). Farmacovigilanza su vaccini COVID-19. https://www.aifa.gov.it/farmacovigilanza-vaccini-covid-19 . Updated and accessed 26 Mar 2021.
Klein NP, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson KE, Donahue JG, Kharbanda EO, Naleway A, Nelson JC, Xu S, Yih WK, Glanz JM, Williams JTB, Hambidge SJ, Lewin BJ, Shimabukuro TT, DeStefano F, Weintraub ES. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA. 2021. https://doi.org/10.1001/jama.2021.15072 .
doi: 10.1001/jama.2021.15072
pubmed: 34477808
pmcid: 8511971
Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111. https://doi.org/10.1016/S0140-6736(20)32661-1 .
doi: 10.1016/S0140-6736(20)32661-1
pubmed: 33306989
pmcid: 7723445
ClinicalTrials.gov. A study of Ad26.COV2.S for the prevention of SARS-CoV-2-mediated COVID-19 in adult participants (ENSEMBLE) https://clinicaltrials.gov/ct2/show/NCT04505722 . Accessed 14 Apr 2021.
World Health Organization. Tracking SARS-CoV-2 variants. 2021. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ . Accessed 2 Aug 2021.
Abu-Raddad LJ, Chemaitelly H, Butt AA, National Study Group for COVID-19 Vaccination. Effectiveness of the BNT162b2 COVID-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med. 2021;385(2):187–9. https://doi.org/10.1056/NEJMc2104974 .
doi: 10.1056/NEJMc2104974
pubmed: 33951357
Emary KRW, Golubchik T, Aley PK et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021;397:1351–62.
doi: 10.1016/S0140-6736(21)00628-0
pubmed: 33798499
pmcid: 8009612
Sadoff J, Gray G, Vandebosch A, Cárdenas V et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19. N Engl J Med. 2021;384:2187–201.
doi: 10.1056/NEJMoa2101544
pubmed: 33882225
Wu K, Werner AP, Koch M et al. Serum neutralizing activity elicited by mRNA-1273 vaccine. N Engl J Med. 2021;384:1468–70.
doi: 10.1056/NEJMc2102179
pubmed: 33730471
Campbell F, Archer B, Laurenson-Schafer H et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Euro Surveill. 2021;26:2100509.
doi: 10.2807/1560-7917.ES.2021.26.24.2100509
pmcid: 8212592
Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 COVID-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384(20):1885–98. https://doi.org/10.1056/NEJMoa2102214 .
doi: 10.1056/NEJMoa2102214
pubmed: 33725432
Liu J, Liu Y, Xia H, et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 2021;596(7871):273–5. https://doi.org/10.1038/s41586-021-03693-y .
doi: 10.1038/s41586-021-03693-y
pubmed: 34111888
CBS News. Delta variant of COVID-19 likely to become dominant U.S. strain, Gottlieb says—CBS News. 2021 https://www.cbsnews.com/news/covid-19-delta-varient-dominant-strain-likely/ . Accessed 2 Aug 2021.
Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021. https://doi.org/10.1038/s41577-021-00592-1 .
doi: 10.1038/s41577-021-00592-1
pubmed: 34373623
pmcid: 8351583
Shahidi-Dadras M, Tabary M, Robati RM, Araghi F, Dadkhahfar S. Psoriasis and risk of the COVID-19: is there a role for angiotensin converting enzyme (ACE)? J Dermatolog Treat. 2020. https://doi.org/10.1080/09546634.2020.1782819 .
doi: 10.1080/09546634.2020.1782819
pubmed: 32893725
Diotallevi F, Campanati A, Bianchelli T, et al. Skin involvement in SARS-CoV-2 infection: case series. J Med Virol. 2020;92(11):2332–4. https://doi.org/10.1002/jmv.26012 .
doi: 10.1002/jmv.26012
pubmed: 32410241
Campanati A, Brisigotti V, Diotallevi F, et al. Active implications for dermatologists in “SARS-CoV-2 ERA”: personal experience and review of literature. J Eur Acad Dermatol Venereol. 2020;34(8):1626–32. https://doi.org/10.1111/jdv.16646 .
doi: 10.1111/jdv.16646
pubmed: 32426855
Rizzetto G, Diotallevi F, Campanati A, et al. Telogen effluvium related to post severe SARS-CoV-2 infection: clinical aspects and our management experience. Dermatol Ther. 2020. https://doi.org/10.1111/dth.14547 .
doi: 10.1111/dth.14547
pubmed: 33190397
pmcid: 7744849
Jamiolkowski D, Mühleisen B, Müller S, et al. SARS-CoV-2 PCR testing of skin for COVID-19 diagnostics: a case report. Lancet. 2020;396(10251):598–9. https://doi.org/10.1016/S0140-6736(20)31754-2 .
doi: 10.1016/S0140-6736(20)31754-2
pubmed: 32798450
pmcid: 7426103
Kolivras A, Dehavay F, Delplace D et al. Coronavirus (COVID-19) infection–induced chilblains: a case report with histopathologic findings. JAAD Case Rep. 6(6):489–92
Abdollahimajd F, Niknezhad N, Haghighatkhah HR, et al. Angiotensin-converting enzyme and subclinical atherosclerosis in psoriasis: Is there any association? A case-control study. J Am Acad Dermatol. 2020;82(4):980–81.e1. https://doi.org/10.1016/j.jaad.2018.08.003 .
doi: 10.1016/j.jaad.2018.08.003
pubmed: 30114455
Huskić J, Mulabegović N, Alendar F, et al. Serum and tissue angiotensin converting enzyme in patients with psoriasis. Coll Antropol. 2008;32(4):1215–9.
pubmed: 19149231
Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112–6. https://doi.org/10.1038/nature03712 .
doi: 10.1038/nature03712
pubmed: 16001071
pmcid: 7094998
Giannoni M, Consales V, Campanati A, et al. Homocysteine plasma levels in psoriasis patients: our experience and review of the literature. J Eur Acad Dermatol Venereol. 2015;29(9):1781–5. https://doi.org/10.1111/jdv.13023 .
doi: 10.1111/jdv.13023
pubmed: 25809089
Patrick MT, Zhang H, Wasikowski R, et al. Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies. J Allergy Clin Immunol. 2021;147(3):857–69.e7. https://doi.org/10.1016/j.jaci.2021.01.006 .
doi: 10.1016/j.jaci.2021.01.006
pubmed: 33485957
pmcid: 7825803
Ye L, Lv C, Man G, Song S, Elias PM, Man MQ. Abnormal epidermal barrier recovery in uninvolved skin supports the notion of an epidermal pathogenesis of psoriasis. J Invest Dermatol. 2014;134(11):2843–6. https://doi.org/10.1038/jid.2014.205 .
doi: 10.1038/jid.2014.205
pubmed: 24780930
pmcid: 4199879
Rehbinder EM, Advocaat-Endre KM, Lødrup-Carlsen KC, et al. Predicting skin barrier dysfunction and atopic dermatitis in early infancy. J Allergy Clin Immunol Pract. 2020;8(2):664–73.e5. https://doi.org/10.1016/j.jaip.2019.09.014 .
doi: 10.1016/j.jaip.2019.09.014
pubmed: 31568931
Gardien KL, Baas DC, de Vet HC, Middelkoop E. Transepidermal water loss measured with the Tewameter TM300 in burn scars. Burns. 2016;42(7):1455–62. https://doi.org/10.1016/j.burns.2016.04.018 .
doi: 10.1016/j.burns.2016.04.018
pubmed: 27233677
Plichta JK, Droho S, Curtis BJ, Patel P, Gamelli RL, Radek KA. Local burn injury impairs epithelial permeability and antimicrobial peptide barrier function in distal unburned skin. Crit Care Med. 2014;42(6):e420–31. https://doi.org/10.1097/CCM.0000000000000309 .
doi: 10.1097/CCM.0000000000000309
pubmed: 24717471
pmcid: 4231880
Park A, Iwasaki A. Type I and Type III interferons—induction, signaling, evasion, and application to combat COVID-19. Cell Host Microbe. 2020;27(6):870–8. https://doi.org/10.1016/j.chom.2020.05.008 .
doi: 10.1016/j.chom.2020.05.008
pubmed: 32464097
pmcid: 7255347
Diotallevi F, Campanati A, Radi G, et al. Vaccination against SARS-COV-2 and PSORIASIS: the three things every dermatologist should know. J Eur Acad Dermatol Venereol. 2021. https://doi.org/10.1111/jdv.17256 .
doi: 10.1111/jdv.17256
pubmed: 34755400
pmcid: 8251393
Kutlu Ö, Metin A. A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: will cases of psoriasis increase after COVID-19 pandemic? Dermatol Ther. 2020;33(4):e13383. https://doi.org/10.1111/dth.13383 .
doi: 10.1111/dth.13383
pubmed: 32259878
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan China. Lancet. 2020;395(10223):497–506.
doi: 10.1016/S0140-6736(20)30183-5
pubmed: 31986264
pmcid: 7159299
Öncü INS, Güler D, Gürel G. Exacerbation of psoriasis following hydroxychloroquine in a patient with suspected COVID-19. Dermatol Ther. 2021;34(2):e14806. https://doi.org/10.1111/dth.14806 .
doi: 10.1111/dth.14806
pubmed: 33486832
Ozaras R, Berk A, Ucar DH, Duman H, Kaya F, Mutlu H. COVID-19 and exacerbation of psoriasis. Dermatol Ther. 2020;33(4):e13632. https://doi.org/10.1111/dth.13632 .
doi: 10.1111/dth.13632
pubmed: 32436303
Gananandan K, Sacks B, Ewing I. Guttate psoriasis secondary to COVID-19. BMJ Case Rep. 2020;13(8):e237367. https://doi.org/10.1136/bcr-2020-237367 .
doi: 10.1136/bcr-2020-237367
pubmed: 32784237
pmcid: 7418771
Mathieu RJ, Cobb CBC, Telang GH, Firoz EF. New-onset pustular psoriasis in the setting of severe acute respiratory syndrome coronavirus 2 infection causing coronavirus disease 2019. JAAD Case Rep. 2020;6(12):1360–2. https://doi.org/10.1016/j.jdcr.2020.10.013 .
doi: 10.1016/j.jdcr.2020.10.013
pubmed: 33102669
pmcid: 7566789
Shakoei S, Ghanadan A, Hamzelou S. Pustular psoriasis exacerbated by COVID-19 in a patient with the history of psoriasis. Dermatol Ther. 2020;33(6):e14462. https://doi.org/10.1111/dth.14462 .
doi: 10.1111/dth.14462
pubmed: 33112048
Shahidi Dadras M, Diab R, Ahadi M, Abdollahimajd F. Generalized pustular psoriasis following COVID-19. Dermatol Ther. 2021;34(1):e14595. https://doi.org/10.1111/dth.14595 .
doi: 10.1111/dth.14595
pubmed: 33244885
Samotij D, Gawron E, Szczęch J, Ostańska E, Reich A. Acrodermatitis continua of hallopeau evolving into generalized pustular psoriasis following COVID-19: a case report of a successful treatment with infliximab in combination with acitretin. Biologics. 2021;27(15):107–13. https://doi.org/10.2147/BTT.S302164 .
doi: 10.2147/BTT.S302164
Sun Q, Fathy R, McMahon DE, Freeman EE. COVID-19 vaccines and the skin: The landscape of cutaneous vaccine reactions worldwide. Dermatol Clin. 2021. https://doi.org/10.1016/j.det.2021.05.016 .
Krajewski PK, Matusiak Ł, Szepietowski JC. Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine. J Eur Acad Dermatol Venereol. 2021. https://doi.org/10.1111/jdv.17449 (Epub ahead of print. PMID: 34131967).
doi: 10.1111/jdv.17449
pubmed: 34131967
pmcid: 8447171
Lehmann M, Schorno P, Hunger RE et al. New onset of mainly guttate psoriasis after COVID-19 vaccination: a case report. J Eur Acad Dermatol Venereol. 2021. https://doi.org/10.1111/jdv.17561 .
Onsun N, Kaya G, Işık BG, Güneş B. A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: case report. Health Promot Perspect. 2021;11(2):261–2. https://doi.org/10.34172/hpp.2021.32 .
doi: 10.34172/hpp.2021.32
pubmed: 34195051
pmcid: 8233675
Bostan E, Elmas L, Yel B, Yalici-Armagan B. Exacerbation of plaque psoriasis after inactivated and BNT162b2 mRNA COVID-19 vaccines: a report of two cases. Dermatol Ther. 2021;23:e15110. https://doi.org/10.1111/dth.15110 .
doi: 10.1111/dth.15110
Sotiriou E, Tsentemeidou A, Bakirtzi K, Lallas A, Ioannides D, Vakirlis E. Psoriasis exacerbation after COVID-19 vaccination: a report of 14 cases from a single centre. J Eur Acad Dermatol Venereol. 2021. https://doi.org/10.1111/jdv.17582 .
doi: 10.1111/jdv.17582
pubmed: 34923693
pmcid: 8447325
Priebe GP, Walsh RL, Cederroth TA, et al. IL-17 is a critical component of vaccine- induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa. J Immunol. 2008;181:4965–75.
doi: 10.4049/jimmunol.181.7.4965
pubmed: 18802100
Lin Y, Slight SR, Khader SA. Th17 cytokines and vaccine-induced immunity. Semin Immunopathol. 2010;32:79–90.
doi: 10.1007/s00281-009-0191-2
pubmed: 20112107
pmcid: 2855296
Papp KA, Haraoui B, Kumar D, et al. Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies. J Cutan Med Surg. 2019;23(1):50–74.
doi: 10.1177/1203475418811335
pubmed: 30463418
Crowe SR, Merrill JT, Vista ES, et al. Influenza vaccination responses in human systemic lupus erythematosus: Impact of clinical and demographic features. Arthritis Rheum. 2011;63:2396–406.
doi: 10.1002/art.30388
pubmed: 21598235
pmcid: 3149742
Holvast A, van Assen S, de Haan A, et al. Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus. Arthritis Rheum. 2009;60(8):2438–47. https://doi.org/10.1002/art.24679 .
doi: 10.1002/art.24679
pubmed: 19644961
Ribeiro AC, Guedes LK, Moraes JC, et al. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice. Ann Rheum Dis. 2011;70:2144–7.
doi: 10.1136/ard.2011.152983
pubmed: 21859696
Kapetanovic MC, Nagel J, Nordstrom I, et al. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine. Vaccine. 2017;35:903–8.
doi: 10.1016/j.vaccine.2016.12.068
pubmed: 28081972
Karbasi-Afshar R, Izadi M, Fazel M, Khedmat H. Response of transplant recipients to influenza vaccination based on type of immunosuppression: a meta-analysis. Saudi J Kidney Dis Transpl. 2015;26(5):877–83. https://doi.org/10.4103/1319-2442.164556 .
doi: 10.4103/1319-2442.164556
pubmed: 26354557
Campanati A, Moroncini G, Ganzetti G, et al. Adalimumab modulates angiogenesis in psoriatic skin. Eur J Inflamm. 2013;11:489–98.
doi: 10.1177/1721727X1301100218
Radi G, Campanati A, Diotallevi F, Bianchelli T, Offidani A. Novel therapeutic approaches and targets for treatment of psoriasis. Curr Pharm Biotechnol. 2021;22(1):7–31. https://doi.org/10.2174/1389201021666200629150231 .
doi: 10.2174/1389201021666200629150231
pubmed: 32598253
Campanati A, Diotallevi F, Martina E, et al. Safety update of etanercept treatment for moderate to severe plaque psoriasis. Expert Opin Drug Saf. 2020;19(4):439–48. https://doi.org/10.1080/14740338.2020.1740204 .
doi: 10.1080/14740338.2020.1740204
pubmed: 32178543
Martire B, Azzari C, Badolato R, et al. Vaccination in immunocompromised host: recommendations of Italian primary immunodeficiency network centers (IPINET). Vaccine. 2018;36(24):3541–54. https://doi.org/10.1016/j.vaccine.2018.01.061 (Erratum in: Vaccine. 2018 Nov 29;36(50):7753).
doi: 10.1016/j.vaccine.2018.01.061
pubmed: 29426658
National Psoriasis Foundation https://www.psoriasis.org/advance/vaccinating-in-the-time-of-covid/ . Accessed 2 Aug 2021.
Gazzetta Ufficiale della Ufficiale della Repubblica Italiana. Raccomandazioni ad Interim sui Gruppi Target della Vaccinazione Anti SARS-CoV-2/COVID-19. Serie generale—n. 72. Accessed 24 March 2021.
Radi G, Diotallevi F, Campanati A, Offidani A. Global coronavirus pandemic (2019-nCOV): implication for an Italian medium size dermatological clinic of a II level hospital. J Eur Acad Dermatol Venereol. 2020;34(5):e213–4. https://doi.org/10.1111/jdv.16386 .
doi: 10.1111/jdv.16386
pubmed: 32201972